Role of HDL Dysfunction in End-Stage Renal Disease: A Double-Edged Sword

Journal of Renal Nutrition

Volumn 23, Issue 3, 2013, Pages 203-206

  Moradi, Hamid ^a   Vaziri, Nosratola D ^a   Kashyap, Moti L ^a   Said, Hamid M ^a   Kalantar Zadeh, Kamyar ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; BLOOD; CHRONIC KIDNEY FAILURE; DYSLIPIDEMIA; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; KIDNEY FAILURE, CHRONIC; OXIDATIVE STRESS;

EID: 84876706500     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.01.022     Document Type: Review

References (20)

1. Excerpts from the USRDS Annual Data Report: Atlas of End-Stage Renal Disease in the United States 2012, U.S. Renal Data System, Minneapolis, MN.
2. Vaziri N.D., Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int 2006, 10:1-7.
3. Kovesdy C.P., Anderson J.E., Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol 2007, 18:304-311.
4. Noori N., Caulfield M.P., Salameh W.A., et al. Novel lipoprotein subfraction and size measurements in prediction of mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2011, 6:2861-2870.
5. Vaziri N.D. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease. J Ren Nutr 2010, 20:S35-S43.
6. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977, 62:707-714.
7. Gordon D.J., Probstfield J.L., Garrison R.J., et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989, 79:8-15.
8. Okubo K., Ikewaki K., Sakai S., Tada N., Kawaguchi Y., Mochizuki S. Abnormal HDL apolipoprotein A-I and A-II kinetics in hemodialysis patients: a stable isotope study. J Am Soc Nephrol 2004, 15:1008-1015.
9. Fuh M.M., Lee C.M., Jeng C.Y., et al. Effect of chronic renal failure on high-density lipoprotein kinetics. Kidney Int 1990, 37:1295-1300.
10. Moradi H., Said H.M., Vaziri N.D. Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production. Transl Res 2012, Available at:. http://www.ncbi.nlm.nih.gov/pubmed/23219399.
11. Vekic J., Zeljkovic A., Bogavac-Stanojevic N., et al. Cox proportional hazard model analysis of survival in end-stage renal disease patients with small-sized high-density lipoprotein particles. Clin Biochem 2011, 44:635-641.
12. Holzer M., Birner-Gruenberger R., Stojakovic T., et al. Uremia alters HDL composition and function. J Am Soc Nephrol 2011, 22:1631-1641.
13. Vaziri N.D., Moradi H., Pahl M.V., Fogelman A.M., Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009, 76:437-444.
14. Moradi H., Pahl M.V., Elahimehr R., Vaziri N.D. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009, 153:77-85.
15. Kalantar-Zadeh K., Kopple J.D., Kamranpour N., Fogelman A.M., Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007, 72:1149-1156.
16. Kilpatrick R.D., McAllister C.J., Kovesdy C.P., Derose S.F., Kopple J.D., Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol 2007, 18:293-303.
17. Navab M., Reddy S., Van Lenten B.J., et al. Role of dysfunctional HDL in atherosclerosis. J Lipid Res 2008, 50:S145-S149.
18. Honda H., Ueda M., Kojima S., et al. Oxidized high-density lipoprotein as a risk factor for cardiovascular events in prevalent hemodialysis patients. Atherosclerosis 2012, 220:493-501.
19. Weichhart T., Kopecky C., Kubicek M., et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012, 23:934-947.
20. Yamamoto S., Yancey P.G., Ikizler T.A., et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol 2012, 60:2372-2379.